Portfolio company Quartet Medicine Announces Strategic Partnership with Merck

Apollo Endosurgery receives FDA approval for an innovative non-surgical weight loss solution

Portfolio company Tigercat Pharma announces positive Phase II results

Apollo Endosurgery’s LAP-BAND System featured on “The Dr. Oz Show”

miRagen compound reverses pulmonary fibrosis

BiO2 enrolls subjects in Early Feasibility Pilot Study

Tigercat Pharma doses first patient in Prurigo Nodularis Phase II Study

Portfolio company Apollo Endosurgery completes acquisition of obesity intervention division

Remeditex supports promising research with San Antonio scientist.

Portfolio company miRagen named one of the most promising biotech companies of 2012. 19, 2012/

Remeditex Ventures funds innovative medical device company.

Remeditex Ventures leads Series B financing in Boulder based microRNA company, miRagen. 24, 2012/

Remeditex is a key investor in an Austin based medical device company.$47-6M-Financing.aspx

Remeditex supports an early stage Dallas-based oncology company